Coronavirus Update: FDA Pulls Hydroxychloroquine Emergency Authorization, Germany Acquires Stake In CureVac
Praise And Blame For Actions On Controversial Drug
Plus news on the German government's decision to by a 23% stake in mRNA vaccines company CureVac, and Lilly taking Olumiant into Phase III.
You may also be interested in...
How COVID-19 Defined 2020 For Biopharma
Development of vaccines usually takes years, but drug makers whittled the process down to a matter of months amid a concerted response to a global health threat.
Lilly’s Olumiant Could Get Blood Clot Redemption With EUA For COVID
When the US FDA approved Olumiant (baricitinib) for RA, it insisted on a lower dose because of fears of blood clots. Now that an NIH trial has shown that the product plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized COVID patients, Olumaint may get an emergency use authorization from FDA to treat a condition that itself causes blood clots. That doesn't mean the black box is going away; it's just a reminder that there is as much magic and mystery to medicine sometimes as there is science.
Lilly’s Olumiant Cuts COVID-19 Hospital Stays By One Day
Olumiant (baricitinib) plus Gilead’s Veklury (remdesivir) provided a statistically significant reduction in time to recovery versus remdesivir alone for hospitalized patients in US NIAID’s ACTT-2 clinical trial.